Commercial-stage biopharma developing and commercializing innovative monoclonal and bispecific antibodies, including a fully human anti-PD-1 mAb approved for Hodgkin’s lymphoma and cervical cancer and being evaluated across multiple solid tumors and combination regimens. Targets oncology patients with patient-centered cancer immunotherapies offering high response rates and improved long-term survival, with a pipeline that includes LAG‑3 and other next-generation antibody therapies.